NASDAQ:STSA
Satsuma Pharmaceuticals, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.satsumarx.comipo date
Sep 13, 2019
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprie...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus